Sullivan Christopher Ryan — SEC insider filings
SEC reporting owner CIK 1810417. 23 insider filings on record with FilingPulse; latest filed 2026-09-18.
Transaction summary — filings shown
Covers all 23 filings on record, filed 2020-12-14 to 2026-09-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 3 filings — 6,561 shares, $14,853 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 17 legs across 7 filings — 193,784 shares, $3,723,035 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 33.
- Largest priced transaction: sale of 37,945 shares @ $19.85 ($753,333) in Avalo Therapeutics, Inc., filed 2026-08-19.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | Chief Financial Officer | 23 | 3 legs · 6,561 sh · $14,853 | 17 legs · 193,784 sh · $3,723,035 | 33 |
Insider filings — Sullivan Christopher Ryan
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 12,394 @ $9.88 · Sale (S): 12,394 @ $16.33 · Option exercise (M): 12,394 (derivative) @ $0 | EDGAR |
| 2026-09-11 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 10,185 @ $8.04 · Sale (S): 10,185 @ $17.62 · Option exercise (M): 10,185 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 37,945 @ $9.88 · Option exercise (M): 2,876 @ $9.88 · Sale (S): 37,945 @ $19.85 · Sale (S): 3,749 @ $19.94 · Option exercise (M): 31,031 @ $9.88 · Sale (S): 31,031 @ $20.05 · +3 more | EDGAR |
| 2026-06-12 | 4 | Avalo Therapeutics, Inc. (AVTX) | Tax withholding (F): 138 @ $13.10 | EDGAR |
| 2026-05-26 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 39,900 @ $0 | EDGAR |
| 2026-05-11 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 18,606 @ $9.88 · Sale (S): 18,606 @ $24.12 · Option exercise (M): 18,606 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 47,000 @ $8.04 · Sale (S): 13,834 @ $18.55 · Sale (S): 12,347 @ $19.28 · Sale (S): 2,700 @ $20.76 · Sale (S): 9,219 @ $21.37 · Sale (S): 8,900 @ $22.57 · +1 more | EDGAR |
| 2026-05-01 | 4 | Avalo Therapeutics, Inc. (AVTX) | Sale (S): 8,458 @ $13.09 · Sale (S): 8,457 @ $13.23 | EDGAR |
| 2026-04-03 | 4 | Avalo Therapeutics, Inc. (AVTX) | Sale (S): 500 @ $15.86 · Sale (S): 7,479 @ $16.83 · Sale (S): 6,200 @ $17.02 · Sale (S): 1,780 @ $17.57 | EDGAR |
| 2026-03-31 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 24,200 · Tax withholding (F): 8,241 @ $13.89 · Option exercise (M): 24,200 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2025-12-12 | 4 | Avalo Therapeutics, Inc. (AVTX) | Tax withholding (F): 155 @ $4.10 | EDGAR |
| 2025-04-01 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 24,200 · Tax withholding (F): 7,285 @ $8.46 · Option exercise (M): 24,200 (derivative) @ $0 | EDGAR |
| 2025-01-30 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 163,000 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 186,700 (derivative) @ $0 · Grant/award (A): 72,600 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | Avalo Therapeutics, Inc. (AVTX) | Purchase (P): 511 @ $3.42 | EDGAR |
| 2023-05-17 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-02-15 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-10-07 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2022-03-10 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 400,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2021-12-14 | 4 | Avalo Therapeutics, Inc. (AVTX) | Purchase (P): 955 @ $1.57 | EDGAR |
| 2021-01-28 | 4 | Cerecor Inc. (CERC) | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2020-12-14 | 4 | Cerecor Inc. (CERC) | Purchase (P): 5,095 @ $2.28 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-12-09 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1810417 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs